戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tial diameter, respectively, after 15 min of suffusion.
2 mination (94% for rash, 100% for hemorrhagic suffusion, and 95% for signs of secondary infection), ch
3 % for the ear canal to 99.7% for hemorrhagic suffusion) for all variables.
4                                        Prior suffusion of excess L-arginine prevented the increase in
5                                              Suffusion of gingipain RgpA (GRgpA) elicited a significa
6 on were also measured, both before and after suffusion of NMA.
7   EDR impairment was reversed by adventitial suffusion of superoxide dismutase (SOD) of aortas from w
8  intravital microscopy, we found that 20-min suffusion of the extract elicited significant concentrat
9                             In both studies, suffusion of the vessels was performed with filter-steri
10 diameter, n = 41) microvessels following the suffusion of vasoactive drugs was measured with video ca
11                                              Suffusion of venules with this agonist stopped flow prom
12 nitroindazole (7-NI), followed by successive suffusions of the cGMP analogue, 8-bromo-cGMP (8Br-cGMP)
13 esis, addition of 10(-4) M furosemide to the suffusion still caused significant dilation in arteriole
14 pound 48/80, we examined permeability during suffusion with compound 48/80 (25 microg/ml) in the pres
15                                 For example, suffusion with compound 48/80 (25 microg/ml) increased c
16 disruption of the blood-brain barrier during suffusion with compound 48/80, we examined permeability
17 o 76.6% of initial diameter) after 20 min of suffusion with L-NAME, an inhibitor of NO synthesis.
18                                 In contrast, suffusion with SNAP or SIN-1 markedly increased clearanc
19                                We found that suffusion with tiron (1 mM) did not alter basal permeabi
20 uced slowing of flow was reversed rapidly by suffusion with UFH, provided flow had not already stoppe
21                                       During suffusion with vehicle, clearance of FITC-dextran-10K fr
22 ran (M(w)=10000 Da; FITC-dextran-10K) during suffusion with vehicle, S-nitroso-N-acetylpenicillamine
23 amined changes in arteriolar diameter during suffusion with vehicle, SNAP and SIN-1.